223 related articles for article (PubMed ID: 17054752)
1. Costs of patient management of visceral leishmaniasis in Muzaffarpur, Bihar, India.
Meheus F; Boelaert M; Baltussen R; Sundar S
Trop Med Int Health; 2006 Nov; 11(11):1715-24. PubMed ID: 17054752
[TBL] [Abstract][Full Text] [Related]
2. The economic impact of visceral leishmaniasis on households in Bangladesh.
Anoopa Sharma D; Bern C; Varghese B; Chowdhury R; Haque R; Ali M; Amann J; Ahluwalia IB; Wagatsuma Y; Breiman RF; Maguire JH; McFarland DA
Trop Med Int Health; 2006 May; 11(5):757-64. PubMed ID: 16640630
[TBL] [Abstract][Full Text] [Related]
3. Amphotericin B treatment for Indian visceral leishmaniasis: conventional versus lipid formulations.
Sundar S; Mehta H; Suresh AV; Singh SP; Rai M; Murray HW
Clin Infect Dis; 2004 Feb; 38(3):377-83. PubMed ID: 14727208
[TBL] [Abstract][Full Text] [Related]
4. The economic burden of visceral leishmaniasis for households in Nepal.
Rijal S; Koirala S; Van der Stuyft P; Boelaert M
Trans R Soc Trop Med Hyg; 2006 Sep; 100(9):838-41. PubMed ID: 16406035
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness projections of single and combination therapies for visceral leishmaniasis in Bihar, India.
Olliaro P; Darley S; Laxminarayan R; Sundar S
Trop Med Int Health; 2009 Aug; 14(8):918-25. PubMed ID: 19563434
[TBL] [Abstract][Full Text] [Related]
6. Drug policy for visceral leishmaniasis: a cost-effectiveness analysis.
Vanlerberghe V; Diap G; Guerin PJ; Meheus F; Gerstl S; Van der Stuyft P; Boelaert M
Trop Med Int Health; 2007 Feb; 12(2):274-83. PubMed ID: 17300636
[TBL] [Abstract][Full Text] [Related]
7. Anthropometrically derived dosing and drug costing calculations for treating visceral leishmaniasis in Bihar, India.
Olliaro P; Sundar S
Trop Med Int Health; 2009 Jan; 14(1):88-92. PubMed ID: 19121150
[TBL] [Abstract][Full Text] [Related]
8. The economic impact of visceral leishmaniasis on rural households in one endemic district of Bihar, India.
Sarnoff R; Desai J; Desjeux P; Mittal A; Topno R; Siddiqui NA; Pandey A; Sur D; Das P
Trop Med Int Health; 2010 Jul; 15 Suppl 2():42-9. PubMed ID: 20487423
[TBL] [Abstract][Full Text] [Related]
9. Amphotericin B colloidal dispersion for the treatment of Indian visceral leishmaniasis.
Sundar S; Mehta H; Chhabra A; Singh V; Chauhan V; Desjeux P; Rai M
Clin Infect Dis; 2006 Mar; 42(5):608-13. PubMed ID: 16447104
[TBL] [Abstract][Full Text] [Related]
10. Barriers to treatment for visceral leishmaniasis in hyperendemic areas: India, Bangladesh, Nepal, Brazil and Sudan.
Thornton SJ; Wasan KM; Piecuch A; Lynd LL; Wasan EK
Drug Dev Ind Pharm; 2010 Nov; 36(11):1312-9. PubMed ID: 20545513
[TBL] [Abstract][Full Text] [Related]
11. [Liposomal amphotericin B as treatment for visceral leishmaniasis in Europe, 2009].
Rosenthal E; Delaunay P; Jeandel PY; Haas H; Pomares-Estran C; Marty P
Med Mal Infect; 2009 Oct; 39(10):741-4. PubMed ID: 19783391
[TBL] [Abstract][Full Text] [Related]
12. Single-dose liposomal amphotericin B for visceral leishmaniasis in India.
Sundar S; Chakravarty J; Agarwal D; Rai M; Murray HW
N Engl J Med; 2010 Feb; 362(6):504-12. PubMed ID: 20147716
[TBL] [Abstract][Full Text] [Related]
13. Visceral leishmaniasis (kala-azar)--the Bihar (India) perspective.
Sinha PK; Ranjan A; Singh VP; Das VN; Pandey K; Kumar N; Verma N; Lal CS; Sur D; Manna B; Bhattacharya SK
J Infect; 2006 Jul; 53(1):60-4. PubMed ID: 16269185
[TBL] [Abstract][Full Text] [Related]
14. The poorest of the poor: a poverty appraisal of households affected by visceral leishmaniasis in Bihar, India.
Boelaert M; Meheus F; Sanchez A; Singh SP; Vanlerberghe V; Picado A; Meessen B; Sundar S
Trop Med Int Health; 2009 Jun; 14(6):639-44. PubMed ID: 19392741
[TBL] [Abstract][Full Text] [Related]
15. Single-dose liposomal amphotericin B in the treatment of visceral leishmaniasis in India: a multicenter study.
Sundar S; Jha TK; Thakur CP; Mishra M; Singh VP; Buffels R
Clin Infect Dis; 2003 Sep; 37(6):800-4. PubMed ID: 12955641
[TBL] [Abstract][Full Text] [Related]
16. Drug regimens for visceral leishmaniasis in Mediterranean countries.
Gradoni L; Soteriadou K; Louzir H; Dakkak A; Toz SO; Jaffe C; Dedet JP; Campino L; Cañavate C; Dujardin JC
Trop Med Int Health; 2008 Oct; 13(10):1272-6. PubMed ID: 18764817
[TBL] [Abstract][Full Text] [Related]
17. Household cost-of-illness of visceral leishmaniasis in Bihar, India.
Sundar S; Arora R; Singh SP; Boelaert M; Varghese B
Trop Med Int Health; 2010 Jul; 15 Suppl 2():50-4. PubMed ID: 20487419
[TBL] [Abstract][Full Text] [Related]
18. Antileishmanial activity of nano-amphotericin B deoxycholate.
Manandhar KD; Yadav TP; Prajapati VK; Kumar S; Rai M; Dube A; Srivastava ON; Sundar S
J Antimicrob Chemother; 2008 Aug; 62(2):376-80. PubMed ID: 18453526
[TBL] [Abstract][Full Text] [Related]
19. The direct costs of treating human visceral leishmaniasis in Brazil.
Assis TSM; Rosa DCP; Teixeira EM; Cota G; Azeredo-da-Silva ALF; Werneck G; Rabello A
Rev Soc Bras Med Trop; 2017; 50(4):478-482. PubMed ID: 28954068
[TBL] [Abstract][Full Text] [Related]
20. Management of visceral leishmaniasis: Indian perspective.
Agrawal S; Rai M; Sundar S
J Postgrad Med; 2005; 51 Suppl 1():S53-7. PubMed ID: 16519257
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
